Related Experiment Video
Updated: Nov 15, 2025

Cardiac Magnetic Resonance for the Evaluation of Suspected Cardiac Thrombus: Conventional and Emerging Techniques
Published on: June 11, 2019
Location of recurrent cardiovascular events and anticardiolipin antibodies
Javier Galán-González1, Sergio Rico-Martín2, Julián F Calderón-García2
1Department of Internal Medicine, Hospital San Pedro Alcántara, Cáceres, Spain.
Insights
Anticardiolipin (aCL) antibodies increase the risk of distal artery ischemic events, such as stroke or leg events, but not coronary artery events in patients with symptomatic artery disease.
Area of Science:
- Cardiovascular Medicine
- Immunology
- Vascular Biology
Background:
- The link between anticardiolipin (aCL) antibodies and cardiovascular events is not fully understood and may differ based on arterial location.
- Previous research has yielded uncertain findings regarding the association between aCL antibodies and ischemic events.
Purpose of the Study:
- To investigate the relationship between anticardiolipin antibodies and the risk of subsequent ischemic events in different arterial locations.
- To determine if aCL antibodies are an independent risk factor for specific types of cardiovascular events.
Main Methods:
- The study utilized data from the FRENA registry, an ongoing registry of stable outpatients with symptomatic coronary artery disease (CAD), cerebrovascular disease (CVD), or peripheral artery disease (PAD).
- Researchers cross-referenced the rate of subsequent ischemic events with the presence of aCL antibodies (any isotype, IgG, or IgM).
- Multivariate Cox analysis was performed to adjust for relevant clinical covariates.
Main Results:
- Out of 1387 recruited patients, 120 (8.7%) had positive aCL antibody levels.
- Patients with positive aCL antibodies showed a higher risk of distal artery events (ischemic stroke or critical leg events) compared to those with undetectable or low levels (rate ratio: 1.66).
- Multivariate analysis confirmed that aCL antibody positivity is an independent risk factor for distal events (hazard ratio: 1.60; P < .05), but no association with coronary events was found.
Conclusions:
- Anticardiolipin antibody positivity is linked to an increased risk of subsequent ischemic events in distal arteries (cerebral or leg arteries).
- The study found no association between aCL antibodies and coronary artery events.
- Anticardiolipin antibodies appear to have a differential impact on the location of ischemic events in patients with symptomatic artery disease.
Background:
The relationship between anticardiolipin (aCL) antibodies and cardiovascular events is uncertain and may vary according to arterial location.
Materials And Methods:
FRENA is an ongoing registry of stable outpatients with symptomatic coronary artery disease (CAD), cerebrovascular disease (CVD) or peripheral artery disease (PAD). The rate of subsequent ischaemic events was cross-referenced with the presence of aCL antibodies (any isotype, IgG or IgM).
Results:
As of June 2017, 1387 stable outpatients were recruited. Of these, 120 (8.7%) showed positive levels of aCL antibodies. Over an average follow-up of 18 months, 250 patients developed subsequent events: 101 myocardial infarction, 57 ischaemic stroke and 92 critical leg events. Patients with positive aCL antibodies had a higher risk of distal artery events (a composite of ischaemic stroke or critical leg events) than patients with undetectable or low levels (rate ratio: 1.66; 95% CI: 1.07-2.60). However, an association with central coronary events was not found. The multivariate Cox analysis after adjustment for relevant clinical covariates showed that positivity of aCL antibodies is an independent risk factor for distal events (hazard ratio: 1.60; 95% CI: 1.01-2.55; P < .05).
Conclusions:
Positivity of aCL antibodies is associated with an increased risk of subsequent distal artery ischaemic events (cerebral or leg arteries) but not coronary artery events. Anticardiolipin antibodies appear to have a different relationship on the localisation of ischaemic events in patients with symptomatic artery disease.
More Related Videos
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Endocarditis II: Clinical Features of Infective Endocarditis
Pericarditis II: Clinical Features and Diagnostic Tests
Acute Coronary Syndrome III: Diagnostic Studies
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Myocarditis II: Clinical Features and Diagnostic Tests

